key: cord-0922807-punn707v authors: Aucoin, Monique; Cardozo, Valentina; McLaren, Meagan D.; Garber, Anna; Remy, Daniella; Baker, Joy; Gratton, Adam; Kala, Mohammed Ali; Monteiro, Sasha; Warder, Cara; Perciballi, Alessandra; Cooley, Kieran title: A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19? date: 2021-07-29 journal: Metabol Open DOI: 10.1016/j.metop.2021.100115 sha: 4eb4bcb3d30b4eb0bb866b510310348d18ac8d06 doc_id: 922807 cord_uid: punn707v COVID-19 is the respiratory illness caused by the novel coronavirus, SARS-CoV-2. Cytokine storm appears to be a factor in COVID-19 mortality. Echinacea species have been used historically for immune modulation. A previous rapid review suggested that Echinacea supplementation may decrease the levels of pro-inflammatory cytokines involved in cytokine storm. The objective of the present systematic review was to identify all research that has assessed changes in levels of cytokines relevant to cytokine storm in response to administration of Echinacea supplementation. The following databases were searched: Medline (Ovid), AMED (Ovid), CINAHL (EBSCO), EMBASE (Ovid). Title and abstract screening, full text screening, and data extraction were completed in duplicate using a piloted extraction template. Risk of bias assessment was completed. Qualitative analysis was used to assess for trends in cytokine level changes. The search identified 279 unique publications. After full text screening, 105 studies met criteria for inclusion including 13 human studies, 24 animal studies, and 71 in vitro or ex vivo studies. The data suggest that Echinacea supplementation may be associated with a decrease in the pro-inflammatory cytokines IL-6, IL-8, and TNF, as well as an increase in the anti-inflammatory cytokine IL-10. The risk of bias in the included studies was generally high. While there is currently no substantive research on the therapeutic effects of Echinacea in the management of either cytokine storm or COVID-19, the present evidence related to the herb's impact on cytokine levels suggests that further research may be warranted in the form of a clinical trial involving patients with COVID-19. In early January of 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the agent responsible for coronavirus disease 2019 (COVID-19)(1). As of June 2021, the global spread of this virus has led to a pandemic with approximately 176 million confirmed cases, including over 3.8 million deaths worldwide(2). While the majority of COVID-19 patients experience mild to moderate flu-like symptoms (including fever, myalgia or fatigue, and dry cough), severe cases may lead to the development of complications such as acute respiratory distress syndrome (ARDS) and multiple-organ failure (3) . Current scientific literature suggests that "cytokine storm"' is the main cause of ARDS and multiple organ failure in COVID-19 patients(4) through a pathologic process involving excessive inflammation and interference with coagulation leading to clot formation, organ tissue damage (notably in the lungs), multiple organ dysfunction syndrome, septic shock and ultimately death(1, 5). Cytokine storm, also known as cytokine release syndrome, is a phenomenon observed in response to a number of viral infections and is characterized by a rapid release of pro-inflammatory cytokines (6) . A recent literature review proposed a unified characterization of cytokine storm based on three criteria: "elevated cytokine levels, acute systemic inflammatory symptoms and secondary organ dysfunction beyond that which could be attributed to a normal response to a pathogen, if a pathogen is present'' (7) . Cytokines involved in cytokine storm include proinflammatory interleukin (IL)-6, IL-8, IL-1β, IL-12 and tumor necrosis factor (TNF), while other cytokines such as IL-10 inhibit the process through an anti-inflammatory effect (6) . When considering the role of cytokines in COVID-19 specifically, it has been observed that higher levels of IL-6, IL-8 and TNF, at the time of admission, were associated with significantly lower rates of survival after adjusting for demographics and comorbidities as confounding variables. (8) An association between higher IL-6 and IL-8 levels and increasing disease severity was also observed (8) . In another cohort of COVID-19 patients, highly impaired Interferon (IFN) type 1 response was consistent among severe and critically ill patients. (9) Decreased levels of INF-α and IFN-β were associated with ongoing elevation in blood viral load and an over-active response of proinflammatory modulators TNF and IL-6(9). Barrett pallida-treated mice demonstrated statistically significantly higher production of IL-4 (p=0.046) and increased IL-10 production (p=0.057) -no effect on IL-6 by any of the preparation -Statistically significantly increased IL-2 (p<0.035) -no effect on IL-12 production - The changes in cytokine levels that followed Echinacea supplementation are presented in Figure 2 . Results are presented for the cytokines relevant to the progression of cytokine storm. Among the human studies, decreased levels of the pro-inflammatory cytokine IL-6, IL-8, and TNF were reported by 57, 50, and 62% of studies that measured these cytokines, respectively. Among the animal studies decreased levels of proinflammatory cytokines IL-1, IL-6, and TNF, were reported by 73, 78, 74% of studies that measured these cytokines, respectively. However, increased levels of the pro-inflammatory cytokine IL-2 were reported by 57% of animal studies. In addition, an increase in levels of the antiinflammatory cytokine IL-10 were reported by 57% of animal studies that measured this cytokine. Among the cell culture studies, decreased levels of pro-inflammatory cytokines IL-6, IL-8, CCL2, CCCL3, and CCL4 were reported by 63, 70, 67, 75, 71% of studies that measured these cytokines, respectively. Moreover, nearly two thirds of the cell culture studies that measured levels of the anti-inflammatory cytokine IL-10 reported an increase. IFN levels were increased in the majority of human, animal, and cell culture studies; while this cytokine is considered to be pro-inflammatory, decreased levels of IFN have been detected among COVID-19 patients. None of the studies reported cases of cytokine storm. The results of the risk of bias assessments for the human RCT and non-RCT studies are presented in Figures 3 and 4 . In total, six of these studies had a "high risk of bias", two studies had "some concerns" or "moderate risk of bias" and two studies had "low risk of bias". Among the pre-post human studies, two received a rating of "fair" and one received a rating of "poor". Among the animal studies, each one received a rating of "probably high risk of bias" in at least one category. Three received a rating of "definitely high risk of bias" in one category. Additional information on the risk of bias assessment for the pre-post and animal studies is found in Supplemental File 2. Among the cell culture studies, thirty-eight (55%) received as score of 1 corresponding to "reliable without restrictions". Thirty-one (45 %) received a score of 3 corresponding to "unreliable". J o u r n a l P r e -p r o o f The present systematic review identified all human, animal, and cell culture data reporting the impact of Echinacea supplementation on cytokine levels. The data suggest that Echinacea supplementation may be associated with a decrease in the pro-inflammatory cytokines IL-6, IL-8 and TNF as well as an increase in the anti-inflammatory cytokine IL-10. In addition, it may be associated with an increase in IFN, a pro-inflammatory cytokine reported to be low in patients with COVID-19. Overall, the findings of the human and animal studies were more likely to report primarily anti-inflammatory effects. Ex vivo and in vitro studies demonstrated more of a mixture of pro-and anti-inflammatory effects; however, given that they were conducted in the isolation of cell culture rather than in the context of a highly complex, functioning immune system, the results may be less relevant to use in humans. The findings suggest that the use of Echinacea supplementation may be useful in the prevention or management of COVID-19-related cytokine storm in humans, however further targeted studies are needed. Levels of IL-6 and TNF both independently predict COVID-19 disease severity and mortality (8) and may be important therapeutic targets. Therapies aimed at inhibiting these cytokines have demonstrated improvements in the clinical course of severely ill COVID-19 patients. A metaanalysis of studies administering the IL-6 receptor monoclonal antibody tocilizumab to patients with severe COVID-19 revealed a reduction in mortality and the need for mechanical ventilation (132) . The effects of other immunomodulatory agents including anakinra, an inhibitor of IL-1, and sarilumab and siltuximab, inhibitors of IL-6, were inconclusive (133) . Observational registry data from patients with inflammatory bowel disease who contracted COVID-19 suggest a possible benefit from taking anti-TNF medication in terms of a composite outcome of death or hospital admission, however not with either outcome alone. (134) A call to prioritize the study of anti-TNF therapy has been made (134) . Because IL-6 and TNF are independently associated with clinical outcomes, it has been hypothesized that therapy targeted at the inhibition of both cytokines simultaneously may yield additional benefit and warrant study (8) . Echinacea may decrease production of these two cytokines. Among the studies identified in the present review, more studies reported an increase in IFN production than a decrease following Echinacea supplementation. While IFN-α and β are considered proinflammatory in nature, they also play a critical role in exerting an antiviral effect. Observation of depressed levels of IFN-α and β among COVID-19 patients has occurred (9) . While the trial reporting this finding was primarily cross-sectional, sequential assessment found that the depressed levels of IFN-α preceded worsening of disease severity and transfer to more intensive care (9) . The virus SARS-CoV, the causative agent of severe acute respiratory syndrome (SARS), inhibits production of IFNs in order to diminish the innate immune response of the host (135) . A need to explore therapeutic approaches to increase IFN in the treatment of COVID-19 has been proposed(9). Additional evidence that may be considered regarding the potential usefulness of Echinacea in the management of COVID-19 include the herb's ability to decrease the severity and duration of acute respiratory tract infections (22) and in vitro data demonstrating direct antiviral effect of Echinacea against several coronaviruses including SARS-CoV-2(136). The present review has several strengths and limitations. Strengths of the review include a rigorous search strategy that was conducted in multiple databases, as well as duplicate screening and data extraction. The review process is limited by a high level of heterogeneity among the included studies and subsequently, the inability to complete meta-analysis. The findings are limited by the high risk of bias found in many of the included studies. They are also limited by the fact that none of the studies assessed the impact of Echinacea on cytokine changes in patients or models of COVID-19. Many of the human studies involved healthy participants or participants with relatively mild infections such as the common cold. The animal and cell culture studies used a variety of immune stimulating agents such as lipopolysaccharide (LPS), bacterial and viral infections. While animal models of cytokine storm exist (137) , none were used by the studies included in the present review. These factors may decrease the generalizability of the findings to the treatment of COVID-19. Similarly, the studies did not assess the changes in cytokine levels in models of cytokine storm. Cytokine storm is a complex syndrome involving cascades of interdependent inflammatory mediators which changes over the course of clinical progression. Defining this condition has been challenging due to the difficulty of differentiating a dysregulated immune response from a physiologic response to a severe infection (7). Cytokines play an important role in the host response to an infection but at the same time, may cause harm to the host when released in excess. It has been hypothesized that inhibition of cytokine signaling could impair clearance of SARS-CoV-2, and result in worse outcomes such as secondary infections; this has been previously observed in the treatment of influenza (138) and subsequent to the use of IL-6 inhibitors in COVID-19 patients (133) . These findings may suggest that immune modulation may be appropriate for only a subgroup of COVID-19 patients. Additionally, cytokine production varies over the course of the response to the pathogen. Ideally, the immune response should be proportionate to the severity of the infection and result in a return to homeostasis following clearance of the pathogen (7) . The importance of timing may be relevant to interpreting the findings of the present review. The included studies measured cytokine levels at a variety of timepoints in the course of an infection; the impact of timing may account for some of the heterogeneity in the results presented. It has been hypothesized that the cytokine storm seen in COVID-19 occurs in two stages. The first stage is an underactive initial immune response which fails to adequately clear the virus. Subsequently, in response to the failed clearance, there is an overactive immune response (139) . Changes in the immune response at different time points in the course of disease progression suggest that the timing of different immunomodulatory therapies may be highly important (139) . The findings of the present systematic review suggest that the effect of Echinacea supplementation on cytokines may be predominantly antiinflammatory, including the inhibition of cytokines that play a key role in the progression of severe COVID-19. Investigation of the potential therapeutic role of Echinacea supplementation in the prevention or treatment of cytokine storm due to COVID-19 may be warranted.  Modulation of the immune system has been identified as a possible management strategy in severe COVID-19.  A systematic review of all studies assessing changes in cytokine levels following Echinacea supplementation was undertaken.  Echinacea supplementation may decrease the pro-inflammatory cytokines IL-6, IL-8, and TNF.  Echinacea supplementation may increase the anti-inflammatory cytokine IL-10.  Clinical trials assessing the effectiveness of Echinacea in the treatment of cytokine storm in COVID-19 may be warranted. Human Bronchial Epithelial Cell Line; ConA: Concanavalin A; CXCL/CCL: Chemokine Ligand; CL: Chloroform Layer; DC: Dendritic Cells DMSO: Dimethylsulfoxide; EE: Ethanol Extract; EPP: E. purpurea Polysaccharide; EPS: Extracellular Polymeric Substances; EtOH: Ethanol; g: Gram; GM-CSF: Granulocyte-macrophage Colony-stimulating Factor HaCaT cells: Human Keratinocyte Cells; HL: Hexane Layer; HMC-1: Human Mast Cells; H2O2: Hydrogen Peroxide; IFN: Interferon Monocyte Chemoattractant Protein; MIP: Macrophage Inflammatory Protein; ml: Millilitre; ML: Methane Layer; MNL: Mononuclear Leukocyte; MRSA: Methicillin-resistant Staphylococcus Aureus; MSSA: Methicillin-susceptible Staphylococcus Aureus; NADPH: Nicotinamide adenine dinucleotide phosphate PHA: Phytohemagglutinin; PMA: Phorbol 12-myristate 13-acetate Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL) Into the eye of the cytokine storm An inflammatory cytokine signature predicts COVID-19 severity and survival Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients The cytokine storm and COVID-19 Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Dexamethasone in Hospitalized Patients with Covid-19 Use of echinacea in medicine Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties Echinacea purpurea: Pharmacology, phytochemistry and analysis methods The effect of Echinacea spp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review RoB 2: a revised tool for assessing risk of bias in randomised trials ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions Systematic review and evidence integration for literature-based environmental health science assessments ToxRTool", a new tool to assess the reliability of toxicological data Echinacea for treating the common cold: a randomized trial Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial An evaluation of Echinacea angustifolia in experimental rhinovirus infections. The New England journal of medicine Immunological activity of larch arabinogalactan and Echinacea: A preliminary, randomized, double-blind, placebo-controlled trial The effect of 4 wk of oral echinacea supplementation on serum erythropoietin and indices of erythropoietic status. International journal of sport nutrition and exercise metabolism Oral administration of freshly expressed juice of Echinacea purpurea herbs fail to stimulate the nonspecific immune response in healthy young men: J o u r n a l P r e -p r o o f results of a double-blind, placebo-controlled crossover study Influence of Echinacin (EC31) treatment on the exercise-induced immune response in athletes Content of proinflammatory cytokine in patients with clinical remission of chronic herpes infection during immunocorrection. Bulletin of experimental biology and medicine Application of purified polysaccharides from cell cultures of the plant Echinacea purpurea to test subjects mediates activation of the phagocyte system Immunomodulation mediated by a herbal syrup containing a standardized Echinacea root extract: a pilot study in healthy human subjects on cytokine gene expression Pharmacokinetics and immunomodulatory effect of lipophilic Echinacea extract formulated in softgel capsules. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV Regulation of human immune gene expression as influenced by a commercial blended Echinacea product: preliminary studies Pharmacokinetics and immunomodulatory effects of phytotherapeutic lozenges (bonbons) with Echinacea purpurea extract Echinacea stimulates macrophage function in the lung and spleen of normal rats A comparison of the immunostimulatory effects of the medicinal herbs Echinacea, Ashwagandha and Brahmi Echinacea purpurea aerial extract alters course of influenza infection in mice Effects of cichoric acid extract from Echinacea purpurea on collagen-induced arthritis in rats. The American journal of Chinese medicine The effects of the dietary supplementation of Echinacea purpurea extract and/or vitamin C on the intestinal histomorphology, phagocytic activity, and gene expression of the Nile tilapia Avemar and Echinacea extracts enhance mobilization and homing of CD34(+) stem cells in rats with acute myocardial infarction The effect of aerial parts of Echinacea on the circulating white cell levels and selected immune functions of the aging male Sprague-Dawley rat The protective effect of Echinacea spp. (Echinacea angustifolia and Echinacea purpurea) in a rat colitis model induced by acetic acid. Pakistan journal of pharmaceutical sciences Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections Alkylamides of Echinacea purpurea stimulate alveolar macrophage function in normal rats Effects of oral administration of Echinacea purpurea (American herb) on incidence of spontaneous leukemia caused by recombinant leukemia viruses in AKR/J mice Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines Echinacea purpurea Protects Against Restraint Stress-Induced Immunosuppression in BALB/c Mice Nutrigenomic activity of plant derived compounds in health and disease: Results of a dietary intervention study in dog Echinacea complex--chemical view and anti-asthmatic profile Effects of ginseng and echinacea on cytokine mRNA expression in rats Anti-inflammatory effects of essential oil in Echinacea purpurea L. Pakistan journal of pharmaceutical sciences Enhancement of innate and adaptive immune functions by multiple Echinacea species Influence of extract derived in-vitro cell suspension cultures of Echinacea purpurea against some immunosuppressive effects Post-screening characterization of an acidic polysaccharide from Echinacea purpurea with potent anti-inflammatory properties in vivo Echinacea polysaccharide attenuates lipopolysaccharideinduced acute kidney injury via inhibiting inflammation, oxidative stress and the MAPK signaling pathway Modulatory effect of echinacea purpurea root extract on cisplatin-induced renal toxicity in rats: Antioxidant and anti-inflammatory pathways Echinacea polysaccharide alleviates LPS-induced lung injury via inhibiting inflammation, apoptosis and activation of the TLR4/NF-kappaB signal pathway Modulation of immune response gene expression by echinacea extracts: results of a gene array analysis. Canadian journal of physiology and pharmacology Echinacea and anti-inflammatory cytokine responses: Results of a gene and protein array analysis Echinacea purpurea extracts modulate murine dendritic cell fate and function. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association Human gene expression as a tool to determine horticultural maturity in a bioactive plant (Echinacea purpurea L. Moench) Echinacea-induced cytokine production by human macrophages Echinacea purpurea Root Extract Increases Tumor Necrosis Factor Production by Concanavalin A-Activated Murine Splenocytes Echinacea and trypanasomatid parasite interactions: growthinhibitory and anti-inflammatory effects of Echinacea Echinacea and its alkylamides: effects on the influenza A-induced secretion of cytokines, chemokines, and PGE2 from RAW 264.7 macrophage-like cells Liver enzyme-mediated oxidation of Echinacea purpurea alkylamides: production of novel metabolites and changes in immunomodulatory activity Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts Differential functional genomic effects of anti-inflammatory phytocompounds on immune signaling Immunomodulatory effects of arabinogalactanproteins from Baptisia and Echinacea Immuno-suppressive effect of blocking the CD28 signaling pathway in T-cells by an active component of Echinacea found by a novel pharmaceutical screening method Modulation of ovine neutrophil function and apoptosis by standardized extracts of Echinacea angustifolia, Butea frondosa and Curcuma longa Echinacea purpurea (L.) Moench modulates human T-cell cytokine response Echinacea purpurea Extract Polarizes M1 Macrophages in Murine Bone Marrow-Derived Macrophages Through the Activation of JNK The potency of immunomodulatory herbs may be primarily dependent upon macrophage activation In Vitro Effects of Some Botanicals with Anti-Inflammatory and Antitoxic Activity Mast cell degranulation and calcium influx are inhibited by an Echinacea purpurea extract and the alkylamide dodeca-2E,4E-dienoic acid isobutylamide Comparative metabolomics approach coupled with cell-and gene-based assays for species classification and anti-inflammatory bioactivity validation of Echinacea plants Cytokine production by non-adherent mouse splenocyte cultures to Echinacea extracts Effect of Chicoric Acid on Mast Cell-Mediated Allergic Inflammation in Vitro and in Vivo Echinacea pupurea extracts promote murine dendritic cell maturation by activation of JNK, p38 MAPK and NF-kappaB pathways Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea Cytokine-and interferon-modulating properties of Echinacea spp. root tinctures stored at -20degreeC for 2 years Synthesis and biological evaluation of a series of fatty acid amides from Echinacea Echinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema Effect of plant extracts on H2O2-induced inflammatory gene expression in macrophages Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects Human blood mononuclear cell in vitro cytokine response before and after two different strenuous exercise bouts in the presence of bloodroot and Echinacea extracts. Blood cells, molecules & diseases Effects of Echinacea extracts on macrophage antiviral activities Changes in immunomodulatory properties of Echinacea spp. root infusions and tinctures stored at 4degreeC for four days Echinacea tennesseensis ethanol tinctures harbor cytokine-and proliferation-enhancing capacities Phytochemical and immunomodulatory properties of an Echinacea laevigata (Asteraceae) tincture Year-and-a-half old, dried Echinacea roots retain cytokine-modulating capabilities in an in vitro human older adult model of influenza vaccination Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract Echinacea extracts modulate the pattern of chemokine and cytokine secretion in rhinovirus-infected and uninfected epithelial cells Echinacea as an antiinflammatory agent: the influence of physiologically relevant parameters The efficacy of Echinacea in a 3-D tissue model of human airway epithelium The potential use of Echinacea in acne: control of Propionibacterium acnes growth and inflammation Bactericidal and anti-inflammatory properties of a standardized Echinacea extract (Echinaforce): dual actions against respiratory bacteria Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea purpurea In vitro immunomodulatory effects of herbal products. The American surgeon Effects of a standardized purified dry extract from Echinacea angustifolia on proliferation and interferon gamma secretion of peripheral blood mononuclear cells in dairy heifers. Research in veterinary science Bauer ketones 23 and 24 from Echinacea paradoxa var. paradoxa inhibit lipopolysaccharide-induced nitric oxide, prostaglandin E2 and cytokines in RAW264.7 mouse macrophages Selective cytokine-inducing effects of low dose Echinacea. Bulletin of experimental biology and medicine In vitro and in vivo immune stimulating effects of a new standardized Echinacea angustifolia root extract (PolinaceaTM) Effects of Echinaforce treatment on ex vivo-stimulated blood cells Echinacea alkylamides inhibit interleukin-2 production by Jurkat T cells Role for PPARgamma in IL-2 inhibition in T cells by Echinacea-derived undeca-2E-ene-8,10-diynoic acid isobutylamide Anti-inflammatory activities of Echinacea extracts do not correlate with traditional marker components Correlation of XMAP and ELISA cytokine profiles; development and validation for immunotoxicological studies in vitro. Roumanian archives of microbiology and immunology Alkylamides from echinacea modulate induced immune responses in macrophages Antioxidant and immuno-enhancing effects of Echinacea purpurea Melanin: dietary mucosal immune modulator from Echinacea and other botanical supplements Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells Echinacea-induced macrophage activation Ethanolic Echinacea purpurea Extracts Contain a Mixture of Cytokine-Suppressive and Cytokine-Inducing Compounds, Including Some That Originate from Endophytic Bacteria Prevention of influenza virus induced bacterial superinfection by standardized Echinacea purpurea, via regulation of surface receptor expression in human bronchial epithelial cells Modulatory effects of Echinacea purpurea extracts on human dendritic cells: a cell-and gene-based study Genomics and proteomics of immune modulatory effects of a butanol fraction of echinacea purpurea in human dendritic cells A Comparison of the Immunostimulatory Effects of Polysaccharides from Tetraploid and Diploid Echinacea purpurea The immunoregulatory effect of sulfated Echinacea purpurea polysaccharide on chicken bone marrow-derived dendritic cells Co-cultured adventitious roots of Echinacea pallida and Echinacea purpurea inhibit lipopolysaccharide-induced inflammation via MAPK pathway in mouse peritoneal macrophages Echinacea Purpurea L. modulates human t-cell cytokine response Bioavailability and pharmacokinetics of Echinacea purpurea preparations and their interaction with the immune system Alcohol extracts of Echinacea inhibit production of nitric oxide and tumor necrosis factor-alpha by macrophages in vitro. Food and agricultural immunology Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19 Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment Immunopathogenesis of coronavirus infections: implications for SARS In vitro virucidal activity of Echinaforce(R), an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2 The ACE2-deficient mouse: A model for a cytokine storm-driven inflammation Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Conflict of Interest: The authors declare no conflict of interest.Author contributions: The project was conceived by MA, KC and VC. MA, KC and VC developed the study protocol. The search strategy was conducted by VC. Data extraction was completed by all authors. Preliminary data analysis was completed by MA. All authors contributed to manuscript preparation and approved the final manuscript draft.Acknowledgement: The authors wish to acknowledge the long history of use of Echinacea by the Indigenous peoples of North America.